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Abstract  1 
Cancer patients frequently suffer from fatigue, a complex syndrome associated with loss 2 
of muscle mass, weakness, and depressed mood. Cancer-related fatigue (CRF) can be present at 3 
the time of diagnosis, during treatment, and persists for years after treatment. CRF negatively 4 
influences quality of life, limits functional independence, and is associated with decreased 5 
survival in patients with incurable disease. Currently there are no effective treatments to reduce 6 
CRF. The aim of this study was to use a mouse model of tumor growth and discriminate between 7 
two main components of fatigue: loss of muscle mass/function and altered mood/motivation. 8 
Here we show that tumor growth increased fatigue- and depressive-like behaviors, and reduced 9 
body and muscle mass. Decreased voluntary wheel running activity (VWRA) and increased 10 
depressive-like behavior in the forced swim and sucrose preference tests were evident in tumor-11 
bearing mice within the first two weeks of tumor growth and preceded the loss of body and 12 
muscle mass. At three weeks, tumor-bearing mice had reduced grip strength but this was not 13 
associated with altered expression of myosin isoforms or impaired contractile properties of 14 
muscles. These increases in fatigue and depressive-like behaviors were paralleled by increased 15 
expression of IL-1β mRNA in the cortex and hippocampus. Minocycline administration reduced 16 
tumor-induced expression of IL-1β in the brain, reduced depressive-like behavior, and improved 17 
grip strength without altering muscle mass. Taken together, these results indicate that 18 
neuroinflammation and depressed mood, rather than muscle wasting, contribute to decreased 19 
voluntary activity and precede major changes in muscle contractile properties with tumor 20 
growth.  21 
22 
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1. Introduction  1 
Fatigue is the most common symptom reported by cancer patients before and during 2 
treatment, and can continue for years after completion of treatment (Bower and Lamkin, 2013; 3 
Husson et al., 2013; Minton et al., 2012). It often co-occurs with depression, (Bower et al., 2011; 4 
Kim et al., 2012; Pertl et al., 2013) and reduces quality of life (Vissers et al., 2013). However, 5 
the cause of cancer-related fatigue (CRF) is unknown (Berger et al., 2012) and there are no 6 
effective treatments (Bower and Lamkin, 2013).  7 
Mounting evidence indicates that CRF and depressed mood are associated with elevated 8 
serum levels of pro-inflammatory mediators, including C-reactive protein (Pertl et al., 2013) and 9 
cytokines such as tumor necrosis factor-alpha (TNFα), interleukin (IL)-1β and IL-6 (Saligan and 10 
Kim, 2012; Wood and Weymann, 2013). These cytokines are likely produced by the tumor and 11 
host tissues in response to tumor growth or anti-tumor treatments (Wang et al., 2012). Pro-12 
inflammatory cytokines increase expression of biomarkers of autophagy and the ubiquitin-13 
proteasome pathway in skeletal muscle which reduce muscle mass (Fearon et al., 2012; Sandri, 14 
2013; Toledo et al., 2011). The loss of muscle mass, or sarcopenia, can be seen even before 15 
cancer treatment (Baracos et al., 2010; Cao et al., 2010) and likely explains patient complaints of 16 
exhaustion associated with physical activity and muscle weakness (Hofman et al., 2007).  17 
Systemic increases in pro-inflammatory mediators mount a complex response that is not 18 
limited to the periphery. The central nervous system (CNS) interprets inflammatory responses 19 
that originate in the periphery. Microglia, innate immune cells of the CNS, contribute to the 20 
propagation of inflammatory cytokines and secondary messengers throughout the CNS (Wood 21 
and Weymann, 2013). Increases in brain IL-1β are linked to both muscle atrophy (Braun et al., 22 
2011) and depressed mood (Haroon et al., 2012). Recent evidence from rodent models indicates 23 
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that inflammatory cytokines within the CNS are associated with symptoms of fatigue, such as 1 
decreased voluntary wheel running activity (Carmichael et al., 2006). Although a link between 2 
inflammation and fatigue in cancer patients has been suggested (Bower, 2007), no clear 3 
connection between CNS inflammation and CRF has been reported. 4 
The aim of this study was to discriminate between loss of muscle mass and depressed 5 
mood in a mouse model of CRF. Fatigue was modeled as reduced voluntary wheel running 6 
activity (VWRA) (Novak et al., 2012; Wood et al., 2006; Zombeck et al., 2013) and weakness 7 
was modeled as reduced forelimb grip strength (Murphy et al., 2012). Depressed mood was 8 
modeled using the sucrose preference (Lamkin et al., 2011) and forced swim tests (Pyter et al., 9 
2009). We show that depressive-like behavior and brain cytokine expression were increased and 10 
VWRA was decreased in tumor-bearing mice prior to the loss of muscle mass and decrease in 11 
grip strength. Decreased grip strength, however, was not associated with reduced contractile 12 
properties of skeletal muscle. Administration of minocycline to tumor-bearing mice reduced 13 
inflammatory cytokine expression in the brain, reduced depressive-like behavior, and increased 14 
grip strength with no effects on muscle mass.  These data indicate that grip strength may reflect 15 
motivation or mood as much as muscle strength. Overall, decreased physical activity and 16 
depressive-like behaviors are mediated by pro-inflammatory cytokine expression in the brain of 17 
tumor-bearing mice. 18 
 19 
2. Materials and methods 20 
2.1 Mice 21 
Adult female BALB/c x DBA/2 F1 (CD2F1) adult (10 weeks) mice weighing 20-22 g were 22 
obtained from Charles River Laboratories. Female mice were used because we and others have 23 
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shown that tumor-bearing females maintain their food intake and lose a smaller percent of body 1 
mass than male mice (Cosper and Leinwand, 2011) and male mice often gnaw and bite at the 2 
tumor site (Yang et al., 2014). Mice were housed 1-3 per cage and maintained at 25°C under a 12 3 
h light cycle with ad libitum access to water and rodent chow. All procedures were performed in 4 
accordance with the National Institute of Health Guidelines for the Care and Use of Laboratory 5 
Animals and were approved by The Ohio State University Institutional Animal Care and Use 6 
Committee. 7 
 8 
2.2 Mouse model of tumor-growth 9 
The colon26 adenocarcinoma (colon26) cell line was maintained in culture and prepared for 10 
injection as previously described (Xu et al., 2011). Mice were injected subcutaneously between 11 
the scapulae with 5x105 cells in 0.2 ml of PBS or PBS alone. This tumor cell line secretes IL-6 12 
and TNF-α (Graves et al., 2006) and does not metastasize when injected subcutaneously 13 
(Okayama et al., 2009). Tumor growth is usually palpable by day 7 and mice become moribund 14 
by day 24 of tumor-growth. In the present study, all data collection was completed by day 21 of 15 
tumor growth. Body mass and food and water intake were monitored three times a week for the 16 
first 2 weeks, and daily during the 3rd week. Behavioral data were collected in the range of 1 17 
week (7 day), 2 weeks (12-14 day) and 3 weeks (19-21 day) following tumor cell inoculation. 18 
Except as noted below, mice were euthanized by inhalation of CO2 gas and blood was withdrawn 19 
by cardiac puncture. Hindlimb muscles were dissected, weighed, and snap frozen in liquid 20 
nitrogen until biochemical analyses; tumor mass was removed and weighed; the brain was 21 
quickly dissected and hippocampus and cortex brain tissue were snap frozen in liquid nitrogen.   22 
 23 
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2.3 Oral minocycline administration 1 
Mice were housed 3 per cage for the minocycline study. Mice were provided bottles of water or 2 
water supplemented with 1mg/ml minocycline for a dose of 100 mg/kg/day (Sigma, St. Louis) 3 
starting one day after PBS or tumor cell injection. Water bottles were changed every other day 4 
throughout the study. There were no differences in total fluid intake between any of the 5 
experimental groups (Control-minocyline, Control-vehicle, Tumor-minocycline, and Tumor-6 
Vehicle) (data not shown). 7 
 8 
2.4 Grip strength measurements  9 
Forelimb grip strength was determined as previously described (Murphy et al., 2012). In brief, 10 
each mouse was allowed to grasp a platform with both forelimbs and was pulled by the tail until 11 
it released itself from the platform (Columbus Instruments, model 1027DSM). Peak force 12 
measurements (N) were recorded in five trials and the average was calculated. Because smaller 13 
mice have smaller grip strength, peak force was also normalized to body mass of the animal.  14 
 15 
2.5 Voluntary wheel running activity 16 
Fatigue-like behavior was determined using voluntary wheel running activity as previously 17 
described (Zombeck et al. 2013). Mice were singly housed for studies in which voluntary wheel 18 
running activity (VWRA) was determined. Mice were acclimated to a four inch running wheel in 19 
the cage for one week, and baseline measures (week 0) of VWRA were recorded overnight prior 20 
to injection with tumor cells or PBS. Wheels were again placed in the home cages of all mice 21 
overnight on days 7 (week 1), 14 (week 2) and 19 (week 3) of tumor growth and the total number 22 
of turns was digitally recorded (Columbus Instruments, model 0297-004M).  23 
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 1 
2.6 Home cage locomotor activity 2 
Mice were maintained in their home cage with a floor area of 26 x 20 cm, and activity was video 3 
recorded for 3 minutes. On the video records, cages were divided into 6 identical virtual 4 
rectangles and the number of line crossings was determined.  5 
 6 
2.7 Depressive-like behavior 7 
Depressive-like behavior was determined using resignation in the forced swim test (FST) and 8 
anhedonia in the sucrose preference test, as described previously (Godbout et al., 2008; Henry et 9 
al., 2008). In the FST, mice were placed in an inescapable cylinder (diameter 16 cm, height 10 
30 cm) containing 15 cm of water and behavior was recorded for five min. The latency to 11 
become immobile and the duration of immobility were determined. For the sucrose preference 12 
test, mice were provided two solutions: water or water supplemented with 2% sucrose. Mice 13 
were fluid- and food-deprived for 2 h prior to testing. At the start of the dark phase of the 14 
photoperiod, plain water and the sucrose water were both placed in each home cage overnight 15 
(15 h). At the end of each testing period, the fluid content was measured and the percent of 16 
sucrose preference was determined. 17 
 18 
2.8 In vitro Muscle Contractile Properties and Fatigue Resistance 19 
Contractile properties of freshly isolated hindlimb muscles were determined, as described in 20 
detail previously (Bicer et al., 2009). In brief, mice were euthanized with CO2 inhalation and one 21 
soleus muscle and one EDL muscle were removed and placed in oxygenated Ringer’s solution. 22 
One muscle was maintained in oxygenated Ringer’s solution in a petri dish at room temperature 23 
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while contractile measurements were made on the other muscle. The order in which the soleus 1 
and EDL were studied was alternated between experiments and it was previously determined that 2 
this did not impact the results (Bicer et al., 2009). All of the measurements were made at room 3 
temperature (21.2-23.8oC). The muscle was mounted horizontally in an in vitro apparatus (model 4 
801C, Aurora Scientific, Aurora, Ontario, Canada) and was continuously superfused with 5 
oxygenated Ringer’s solution (137 mM NaCl, 5 mM KCl, 13 mM NaHCO3, 1.8 mM KH2PO4, 2 6 
mM CaCl2, 11 mM glucose, 1 mM MgSO4, and 0.025 mM tubocurarine chloride). One tendon of 7 
the muscle was glued to a wire hook and the other tendon was similarly attached to a force 8 
transducer (model 300B, Aurora Scientific). Care was taken to ensure that none of the glue 9 
contacted the muscle fibers. The hook and transducer were mounted on three-way positioners. 10 
The muscle was set at optimal length by adjusting the position of the hook or transducer, until 11 
maximal twitch force was generated. The muscle was then stimulated to elicit five twitches and 12 
the peak twitch force, time to peak force, and time from peak force to one-half relaxation during 13 
each twitch were recorded. Next, the tetanic force-frequency curve was established using 14 
stimulus trains. The lowest stimulation frequency that yielded the maximal peak tetanic force in 15 
the force-frequency measurements was used to measure peak tetanic force and the time from the 16 
last stimulus to one-half relaxation. Five tetani, spaced 2 minutes apart, were studied in each 17 
muscle and the means were calculated. Maximal twitch and tetanic forces were also normalized 18 
to muscle cross-sectional area which was estimated from muscle mass and length measurements 19 
(Bicer et al., 2009). After a five minute rest, fatigue resistance was measured by stimulating the 20 
muscle with trains at 1 Hz consisting of pulses (pulse duration 0.1 ms) at 70 Hz for 400 ms. A 21 
fatigue index was quantitated as the peak force during the train at 2 minutes divided by the peak 22 
force during the initial train. 23 
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 1 
2.9 In situ contractile properties 2 
Control and tumor-bearing mice were anesthetized with urethane and placed in a supine position 3 
on an in situ apparatus (model 809B, Aurora Scientific). The sciatic nerve was exposed above 4 
the knee joint and the uninsulated end of a stainless steel wire electrode (Biomed Wire AS 631, 5 
Cooner Wire Co.) was placed in contact with the nerve. The other end of the wire was connected 6 
to a stimulator (model 701C, Aurora Scientific) which was gated with another stimulator (Grass 7 
Technologies, model S48). The knee was clamped and the skin overlying the tibialis anterior was 8 
cut. The distal tendon of the muscle was glued to a wire which was hooked to the arm of a force 9 
transducer (model S100-5N, Strain Measurement Devices, Wallingford CT) that was connected 10 
to a custom-built power supply/amplifier. The muscle was set to the length at which the greatest 11 
peak twitch force was generated. The stimulation and recording protocols were identical to the 12 
protocol used to determine in vitro contractile properties. Muscle cross-sectional area was 13 
determined as in the in vitro muscle measurements. Core temperature of the mouse was 14 
maintained with a heating pad. 15 
 16 
2.10 Gel electrophoresis 17 
The preparation of samples and of gels for the analysis of myosin heavy chain (MHC) and light 18 
chain (MLC) isoform composition was identical to that described previously (Bicer et al., 2009). 19 
Briefly, MHC isoforms were run on 8% acrylamide gels with 30% glycerol. MLC isoforms were 20 
analyzed on 12% acrylamide (no glycerol). The gels were silver-stained and the relative amounts 21 
of fast- and slow-type MHC isoforms in each sample were determined relative to total MHC in 22 
the same sample. 23 
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 1 
2.11 RNA isolation and RT-PCR analysis 2 
RNA was isolated from hippocampus and cortex brain sections using the Tri-Reagent protocol 3 
(Sigma) and reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription 4 
kit (Applied Biosystems). Quantitative PCR was performed using the Applied Biosystems 5 
Assay-on-Demand Gene Expression protocol. In brief, experimental cDNA was amplified with 6 
an ABI PRISM 7300-sequence detection system (Applied Biosystems) by real-time PCR and 7 
normalized based on reference cDNA (GAPDH). Data were analyzed with the comparative 8 
threshold cycle method. 9 
 10 
2.12 Immunohistochemistry and digital image analyses 11 
Mice were deeply anesthetized by CO2 inhalation and transcardially perfused with sterile PBS 12 
followed by 4% formaldehyde. Brains were post-fixed in 4% formaldehyde for 24 h and 13 
cryoprotected in 20% sucrose for 48 h. Preserved brains were frozen using dry-ice cooled 14 
isopentane and sectioned (25 µm) using a Microm HM550 cryostat. Iba-1 staining was 15 
performed as previously described (Wohleb et al., 2011). In brief, free-floating sections were 16 
blocked and then incubated with rabbit anti-mouse Iba-1 antibody (Wako Chemicals) overnight 17 
at 4°C. Sections were washed with PBS and incubated with a fluorochrome-conjugated 18 
secondary antibody (Alexa Flour 594). Fluorescent images were visualized using an 19 
epifluorescent Leica DM5000B microscope and were captured using a Leica DFC300 FX 20 
camera and imaging software. Quantitation was assessed using digital image analysis (Donnelly 21 
et al., 2009) in the hippocampus (12 representative images) and prefrontal cortex (6 22 
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representative images) at 20x magnification. Threshold staining was determined using NIH 1 
ImageJ software. Results are reported as the average percent area for Iba-1+ staining. 2 
 3 
2.13 IL-6 ELISA 4 
IL-6 was determined from plasma using the BD OptEIA Mouse IL-6 ELISA, according to the 5 
manufacturer’s instructions (BD Biosciences). Absorbance was read at 450 nm using a Synergy 6 
HT Plate Reader (Bio-tek instruments). The assay was sensitive to 10 ng/ml IL-6 and intra-assay 7 
coefficients of variation were less than 10%. 8 
 9 
2.14 Statistical Analysis 10 
Data were subjected to a Shapiro-Wilk test using Statistical Analysis Systems (SAS) software 11 
(Cary, NC). Observations greater than three interquartile ranges from the first and third quartile 12 
were considered outliers and were excluded in the subsequent analyses. To determine significant 13 
main effects and interactions between main factors, data were analyzed using one-, two-, or 14 
three-way ANOVA using the General Linear Model procedures of SAS. Differences between 15 
group means were evaluated with the t-test using the Least-Significant Difference procedure of 16 
SAS. All data are expressed as treatment means ± standard error of the mean (SEM). 17 
 18 
3. Results  19 
3.1 Tumor growth was associated with muscle loss and muscle weakness  20 
To begin to understand the effects of tumor growth on muscle function and mood, mice were 21 
inoculated subcutaneously between the scapulae with C26 adenocarcinoma cells. Tumor mass 22 
was 0.3 g by 2 weeks and reached an average of 1.3 g (5% of body mass) by 3 weeks 23 
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(F1,24=38.22, p<0.0001, Fig.1A). Body mass of tumor-bearing mice was not different from 1 
healthy controls at 1 and 2 weeks, but was reduced by 3 weeks (F2,30=3.51, p<0.05, Fig.1B). 2 
There was no decline in muscle mass within 2 weeks of tumor growth; however, there was a 3 
significant loss of gastrocnemius muscle mass by three weeks of tumor growth (F1,26=13.17, 4 
p<0.02, Fig.1C). Tumor growth also reduced the mass of tibialis cranialis, soleus, and biceps 5 
brachii muscles (p<0.05 for each, data not shown).  6 
Next, the extent to which loss of muscle mass contributed to muscle weakness was 7 
determined. In this experiment, forelimb grip strength was determined prior to tumor cell 8 
inoculation (week 0) and at weeks 2 and 3 of tumor growth. Tumor growth decreased grip 9 
strength (F1,66=4.72, p<0.03) in a time-dependent manner (F1,66=3.08, p<0.05) (Fig.1D). Grip 10 
strength of tumor-bearing mice was similar to controls at baseline and 2 weeks after tumor cell 11 
inoculation but was decreased compared to controls by  3 weeks (p<0.003, Fig.1D). Similar data 12 
were obtained when grip strength was normalized to body mass (F1,16=8.84, p<0.02, Fig.1E).  13 
 14 
3.2 Effects of tumor growth on contractile properties of skeletal muscle 15 
To better understand the decline in grip strength in tumor-bearing mice, we examined 16 
contractile properties of the soleus and EDL from tumor-bearing mice in vitro at 1, 2, and 3 17 
weeks after tumor cell inoculation and from control mice at 4 weeks after saline injection. 18 
Absolute twitch force (i.e., not normalized with muscle cross-sectional area) in the soleus was 19 
not affected by tumor burden (Table 1). In contrast, absolute tetanic force in the soleus was 20 
significantly reduced after two and three weeks of tumor burden (F1,24=5.468, p<0.007). 21 
Absolute twitch force in the EDL was significantly lower at one, two and three weeks of tumor 22 
burden (F1,24=4.852, p<0.011), as was absolute tetanic force at one and three weeks (F1,24=3.185, 23 
  
 13
p<0.04, Table 2). Peak twitch and tetanic forces normalized to cross sectional area of the muscle 1 
(specific force) were not different from control animals at weeks 1, 2 or 3 of tumor growth in 2 
either the soleus (Table 1) or EDL (Table 2). In the soleus, the time to peak twitch force and the 3 
time to one-half relaxation were significantly longer in tumor-bearing mice, beginning at one 4 
week after inoculation (p<0.05). The time to one-half relaxation of the tetanus was, however, 5 
unaltered by tumor growth. In the EDL, relaxation during the tetanus was not affected by tumor 6 
growth. Moreover, fatigue resistance was not altered in either muscle at weeks 1, 2, or 3 of tumor 7 
growth.  8 
Given the absence of significant effects of tumor growth on normalized muscle force 9 
generation in vitro, in situ contractile analyses were performed on the tibialis anterior muscle at 10 
three weeks of tumor growth. Absolute peak twitch and tetanic forces were lower in the tumor-11 
bearing mice, compared to the control group (F1,12=8.863, p<0.01, Table3). However, the forces 12 
normalized to cross sectional area, kinetics of contraction and relaxation, and fatigue resistance 13 
were not different between control mice and tumor-bearing mice (Table 3).  14 
Myosin heavy chain (MHC) and myosin light chain (MLC) are major determinants of 15 
contractile properties in skeletal muscle. Therefore, we evaluated the MHC and MLC isoform 16 
composition of the soleus and EDL in control and tumor-bearing mice on SDS gels. There were 17 
no differences detected in MHC or MLC isoform expression in either the soleus or EDL between 18 
control and tumor-bearing mice at three weeks of tumor growth (Fig.1S). Overall, these data 19 
indicate that while tumor growth decreased skeletal muscle mass and reduced absolute grip 20 
strength over time, myosin composition and normalized contractile forces of skeletal muscles 21 
were not altered by tumor growth.  22 
 23 
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3.3 Tumor growth increased fatigue- and depressive-like behavior 1 
The lack of effect of tumor growth on normalized contractile force of muscle suggests 2 
that tumor-associated changes in mood might decrease motivation of the tumor-bearing mice to 3 
engage in the grip strength test. To test this hypothesis, mice were evaluated for fatigue and 4 
depressive-like behaviors. In the first experiment, activity was assessed in control and tumor-5 
bearing mice using VWRA before tumor cell inoculation and again 1, 2, and 3 weeks later. 6 
VWRA progressively declined in the tumor-bearing mice (F1,16=15.23, p<0.001) (Fig.2A). 7 
VWRA was decreased by week 2 (p<0.001) of tumor growth, prior to loss of muscle mass, and 8 
was further decreased by week 3 (p<0.001) compared to controls.  9 
To better understand the influence of tumor growth on mood, anhedonia (sucrose 10 
preference) was determined in control and tumor-bearing mice before tumor cell inoculation and 11 
again 1, 2 and 3 weeks of tumor growth. At baseline, all mice preferred drinking sucrose, i.e. 12 
over 80% of total fluid consumed (data not shown). Moreover, control mice maintained a 13 
preference for sucrose at each time point (Fig.2B). In tumor-bearing mice, however, sucrose 14 
preference was decreased (F1,100=4.09, p<0.004) to 56% by 1 week (p<0.006) and 52% by 2 15 
weeks (p<0.05) of tumor growth (Fig.2B).  This decrease in sucrose preference was no longer 16 
present by week three of tumor growth.  17 
 To further examine the effects of tumor growth on mood in tumor-bearing mice, 18 
depressive-like behavior (resignation) was determined at 2 weeks using the forced swim test 19 
(FST). This time point represents a time when sucrose preference and VWRA were decreased in 20 
tumor-bearing mice, but body mass and muscle mass were not different from controls. Because 21 
these evaluations of mood/motivation can be confounded by differences in locomotion, home 22 
cage locomotor activity was determined prior to the FST. There was no difference in home cage 23 
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activity between control and tumor-bearing mice at 2 weeks of tumor growth (Fig.2C). 1 
Nonetheless, tumor-bearing mice were immobile faster (F1,12=7.05, p<0.02, Fig.2D) and spent 2 
more time immobile in the FST compared to controls (F1,12= 43.18, p<0.001, Fig.2E). Overall, 3 
these data indicate that tumor growth was associated with increased depressive-like behavior at 4 
the same time as VWRA was reduced in tumor-bearing mice.   5 
 6 
3.4 Increased IL-1β and IL-6 mRNA expression in the brain of tumor-bearing mice 7 
Our data indicate that tumor growth increased depressive-like behavior and decreased 8 
VWRA prior to reducing grip strength and muscle mass in the tumor-bearing mice. Because 9 
depressed mood is associated with increased levels of inflammatory cytokines within the brain, 10 
IL-1β, IL-6, and TNFα mRNA expression was determined at 2 and 3 weeks in the cortex (CX) 11 
and hippocampus (HPC) of control and tumor-bearing mice. Tumor growth increased IL-1β 12 
mRNA expression in the HPC (F1,44=24.17, p<0.0001) (Fig.3A). For example, IL-1β mRNA was 13 
increased by 2 weeks after tumor cell inoculation (p<0.03) and was further increased by 3 weeks 14 
(p<0.004). A similar pattern for IL-1β mRNA expression was evident in the CX of tumor-15 
bearing mice (F1,37=10.31, p<0.003, Fig.3B). Tumor growth also tended to increase IL-6 mRNA 16 
in the HPC (F1,44=3.3, p=0.08) (Fig.3C) and CX (F1,34=4.15, p<0.05) (Fig.3D) by 3 weeks, but 17 
not by 2 weeks. TNFα mRNA expression was not increased in tumor-bearing mice at either time 18 
point (data not shown). 19 
Next, microglial activated morphology was determined in the HPC and CX of control and 20 
tumor-bearing mice at 3 weeks. Representative images of Iba-1 positive microglia from the HPC 21 
and CX are shown in Fig.3E. There was no difference in Iba-1 immunoreactivity in the HPC 22 
between control mice and tumor mice (top panels). In the CX, however, tumor-bearing mice had 23 
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increased Iba-1 immunoreactivity. Microglia from the brain of tumor mice had larger cell bodies 1 
with thicker and more condensed processes (Fig.3E). Proportional analysis of Iba-1 staining 2 
(Wohleb et al., 2011) confirmed that tumors increased Iba-1 immunoreactivity in the CX 3 
(F1,12=4.65, p=0.05, Fig.3F). Taken together, these data indicate tumor growth was associated 4 
with increased pro-inflammatory cytokine expression in the hippocampus and cortex and 5 
increased Iba-1 immunoreactivity. 6 
 7 
3.5 Minocycline attenuated depressive-like behavior, neuroinflammation, and restored grip 8 
strength in tumor-bearing mice 9 
Reduced VWRA, increased depressive-like behavior, and increased brain expression of IL-1β 10 
were evident by two weeks of tumor growth and preceded the reduction in muscle mass and grip 11 
strength at three weeks. Therefore, minocycline, an anti-inflammatory agent and purported 12 
microglial inhibitor (Nikodemova et al., 2006), was used to determine the extent to which 13 
elevated IL-1β and IL-6 expression in the CNS contributes to altered behavior in tumor-bearing 14 
mice. For this experiment, mice were administered minocycline in their drinking water from day 15 
1 after tumor cell inoculation to the completion of the study.  16 
Depressive-like behavior was determined at 2 weeks of tumor growth using the FST. 17 
Consistent with our earlier finding (Fig. 2E), tumor-bearing mice had an increased total time 18 
immobile in the FST (F1,46=53.83, p<0.001) (Fig.4A). Tumor-bearing mice treated with 19 
minocycline, however, had decreased total time immobile compared to tumor-bearing mice 20 
given water (F(1,46)=7.65, p<0.01) (Fig.4A). At 3 weeks of tumor growth, absolute (data not 21 
shown) and normalized grip strength were decreased in tumor-bearing mice (F1,22=5.88, p<0.03) 22 
(Fig.4B). Administration of minocycline restored the normalized grip strength to the same levels 23 
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as control mice (F1,22=3.75, p=0.07) (Fig. 4B). After the completion of this test, mice were 1 
euthanized and tumor mass, gastrocnemius muscle mass, plasma IL-6 levels and brain IL-1β and 2 
IL-6 mRNA expression were determined. As expected, minocycline intervention had no 3 
significant effect on tumor mass (Fig.4C) or gastrocnemius muscle mass (Fig.4D). Plasma IL-6 4 
was increased in tumor-bearing mice (F1,23=37.04, p<0.001) but was not changed by minocycline 5 
administration (Fig.4E). Consistent with previous results (Fig.3), expression of IL-1β and IL-6 6 
mRNA were increased in the cortex and hippocampus of tumor-bearing mice at 3 weeks of 7 
tumor growth (Fig.5A-D). Minocycline intervention, however, blocked tumor associated 8 
increases in IL-1β and IL-6 mRNA in the hippocampus and cortex (F1,46=5.18, p<0.03, for each). 9 
In conclusion, minocycline intervention had no effect on tumor size or muscle mass, but 10 
ameliorated the tumor-associated effects on neuroinflammation, depressive-like behavior, and 11 
grip strength normalized to body mass.  12 
 13 
4. Discussion  14 
Fatigue is a common and distressing symptom reported by cancer patients before, during, 15 
and after cancer treatments. Patients with CRF often describe muscle weakness and reduced 16 
effort tolerance which have a negative effect on quality of life and functional status (Hofman et 17 
al., 2007). Muscle wasting and depressive symptoms are prevalent in patients with CRF and are 18 
associated with higher mortality rates in cancer patients with persistent or incurable disease 19 
(Mols et al., 2013). Therefore, treatments to reduce fatigue and depression in cancer patients are 20 
needed to increase quality of life and perhaps prolong survival. In this study, a mouse model of    21 
CRF was used to discriminate between loss of muscle mass and altered mood in the onset of 22 
fatigue behaviors. Here we report that tumor-bearing mice demonstrate behaviors of fatigue 23 
  
 18
(decreased VWRA) and depressed mood (resignation and anhedonia) prior to the onset of muscle 1 
fatigue, as determined from in vitro measurements. In addition, the decreases in VWRA and grip 2 
strength in tumor-bearing mice were not associated with decreases in contractile properties of 3 
skeletal muscle. Depressive-like behavior in tumor-bearing mice was associated with increased 4 
expression of IL-1β and IL-6 in the cortex and hippocampus, brain regions associated with mood 5 
and motor activity. Treatment of the tumor-bearing mice with minocycline, an anti-inflammatory 6 
agent and purported microglial inhibitor, did not affect tumor growth or muscle mass. However, 7 
minocyline reduced tumor-induced depressive-like behavior and brain cytokine expression and 8 
improved grip strength in tumor-bearing mice. Overall, these data support the hypothesis that 9 
tumor induced cytokine-dependent changes in mood play a larger role in behaviors of CRF 10 
compared to loss of skeletal muscle mass.  11 
Consistent with other studies, tumor growth was associated with decreased body mass 12 
and muscle mass (Acharyya et al., 2004; Xu et al., 2011). Moreover, reduced muscle mass was 13 
associated with reduced grip strength by three weeks of tumor growth. Although absolute force 14 
generating ability was reduced and was proportional to differences or decreases in muscle cross-15 
sectional area, fundamental contractile properties of the EDL and soleus in vitro, or the tibialis 16 
anterior in situ were not altered by tumor burden (Tables 1-3) (Murphy et al., 2013). The lack of 17 
differences in the in situ contractile properties of muscles of control and tumor-bearing mice, 18 
other than absolute force generation, indicates that the neuromotor innervation was not 19 
significantly impaired by tumor progression. These data are consistent with a clinical study 20 
showing that absolute strength of the quadriceps muscle in cancer patients was decreased, but 21 
was identical to control subjects when normalized to muscle cross sectional area (Weber et al., 22 
2009). Others have reported a decrease in muscle force generation, normalized with cross-23 
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sectional area, in association with cancer cachexia (Roberts et al., 2013; Toth et al., 2013). 1 
Roberts et al. (2013) used a more severe tumor load (same number of tumor cells per injection, 2 
but injected bilaterally in the flank region) and reported a decrease in specific force that was not 3 
observed in the present study. The difference between the previous and current studies suggests 4 
that the greater tumor load caused a decrease in specific force through a mechanism that was 5 
independent of the loss of muscle mass. Murphy and co-workers (2012 and 2013) also report that 6 
specific force generation is not affected by tumor burden, using the same model as in the present 7 
study. Our results demonstrate that motor/behavioral deficits can precede a reduction in specific 8 
force generation or muscle fatigue. 9 
Several previous reports indicate that the myosin heavy chain isoform composition of 10 
skeletal muscle, a major determinant of muscle contractile properties, changes with tumor burden 11 
(Diffee et al., 2002; Taskin et al., 2014), whereas others reported no change in myosin heavy 12 
isoform composition or myosin-based fiber type composition (Johns et al., 2014; Schmitt et al., 13 
2007). Consistent with no change in specific force generation, significant alterations in physical 14 
activity were observed in tumor-bearing mice, compared to control mice, without any detectable 15 
change in myosin isoform expression.  16 
 Reduced VWRA is a widely used model of fatigue in response to immune challenge 17 
(Hopwood et al., 2009) or chemotherapy (Zombeck et al., 2013). A key finding in this study was 18 
that reduced VWRA and depressive-like behavior occurred in tumor-bearing mice prior to 19 
significant weight or muscle loss. The decrease in VWRA was not associated with reduced home 20 
cage activity. These findings indicate that tumor growth did not cause general malaise. Instead, 21 
tumor-bearing mice likely had reduced motivation to run, suggesting that depressed mood plays 22 
a role in CRF (Novak et al., 2012). In support of this idea, tumor-bearing mice showed reduced 23 
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sucrose preference at one and two weeks after tumor cell inoculation, and increased time 1 
immobile in the FST at the two week time point. Other studies have shown that peripheral 2 
tumors induce depressive-like behavior concurrent with reduced body mass in rodents (Lamkin 3 
et al., 2011; Pyter et al., 2009; Yang et al., 2014). Our study, however, shows that depressive-like 4 
behavior occurs early in the course of tumor growth and precedes tumor induced weight loss or 5 
muscle wasting. Of note, the tumor-bearing mice no longer had a reduced preference for sucrose 6 
at the three week time point. This observation suggests that sucrose solution became the 7 
preferred calorie source for mice with significant tumor burden, though we observed no decease 8 
in solid food intake or increase in total fluid intake (data not shown).  9 
CRF involves complex, interacting effects of tumor growth on multiple dimensions 10 
involved in the functional status of the cancer patient. Therefore, the underlying mechanisms of 11 
CRF are unknown but may be related to a heightened inflammatory state. In rodent models of 12 
inflammation and immune activation, elevated IL-1β expression in the brain has been associated 13 
with fatigue and depression (Carmichael et al., 2006; Godbout et al., 2008). In the current study, 14 
we provide several lines of evidence that increased pro-inflammatory cytokine expression in the 15 
brain influences fatigue and depressive-like behaviors in tumor-bearing mice. We observed 16 
increased IL-1β mRNA in the brain, reduced VWRA and depressive-like behavior in tumor-17 
bearing mice with no decrease in home-cage locomotor activity. Furthermore, orally 18 
administered minocycline prevented tumor-induced increases in IL-1β and IL-6 mRNA 19 
expression in the cortex and hippocampus, decreased depressive-like behavior in the FST at two 20 
weeks and increased normalized grip strength at three weeks of tumor growth. The ability of 21 
minocycline to increase relative grip strength without increasing muscle mass indicates that there 22 
is a motivation component to grip strength testing. Minocycline treatment had no effect on 23 
  
 21
plasma IL-6, muscle mass or tumor mass, suggesting that the behavioral effects of minocycline 1 
were related to decreases in neuroinflammation rather than delayed tumor growth or increased 2 
skeletal muscle mass. These results support our overall hypothesis that cytokine-dependent 3 
effects of tumor growth on neuroinflammation play a major role in the co-morbidity of fatigue 4 
and depression in cancer patients (Bower et al., 2011; Kim et al., 2012; Kirkova et al., 2011; 5 
Minton et al., 2012; Phillips and McAuley, 2013). In addition, others have shown that psycho-6 
cognitive therapy is as effective as exercise therapy in reducing fatigue in cancer patients 7 
(Gielissen et al., 2006) which further supports an important role for the affective domain in CRF. 8 
Further study is needed to determine the potential of minocycline to reduce depression and 9 
attenuate fatigue in cancer patients.  10 
 11 
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8. Figure Legends 1 
Figure 1. Tumor growth was associated with muscle mass loss and muscle weakness. Mice 2 
were inoculated s.c. with PBS (Control) or PBS with C26 adenocarcinoma cells (Tumor). A) 3 
Tumor mass, B) body mass, and C) gastrocnemius muscle mass was determined 1, 2, and 3 4 
weeks after inoculation (n=6). D) Grip strength (Newtons) was determined at baseline (day 0) 5 
and then again at 2 and 3 weeks (n=8). E) The normalized grip strength (Newtons of grip 6 
strength to kilograms of body mass) was also determined at the 3 week endpoint (n=8). Data are 7 
expressed as mean ± SEM. Means with * are different from control mice (p<0.05). 8 
 9 
Figure 2. Tumor growth increased fatigue- and depressive-like behavior. A) Voluntary 10 
wheel running activity (VWRA) was determined overnight at baseline and again at 1, 2, and 3 11 
weeks after tumor cell inoculation. B) Sucrose preference was determined 1, 2, and 3 weeks after 12 
tumor cell inoculation. C) Home cage activity was determined 2 weeks after tumor inoculation. 13 
Control and tumor mice were exposed to the forced swim test (FST) at 2 weeks and D) latency to 14 
become immobile and E) total time immobile were determined (n=6). Bars represent the mean ± 15 
SEM. Means with * are different from control (p<0.05). 16 
 17 
Figure 3. Increased IL-1β and IL-6 mRNA expression in the brain of tumor-bearing mice. 18 
IL-1β mRNA expression was determined in the A) hippocampus (HPC) and B) cortex (CX) 2 19 
and 3 weeks after tumor cell injection. IL-6 mRNA was also determined in the C) HPC and D) 20 
CX (n=6). E) Representative images of Iba-1 labeling of microglia in the HPC and CX collected 21 
3 weeks after tumor cell inoculation. Inset includes enlarged image of Iba-1+ cell indicated by 22 
white arrow. Proportional area for Iba-1 labeling in the F) HPC and G) CX (n=6). Data are 23 
  
 27
expressed as mean ± SEM. Means with * are different from control mice (p<0.05) and means 1 
with ‡ are different from Tumor-Week 2 (p<0.05). 2 
 3 
Figure 4. Minocycline attenuated depressive-like behavior and restored grip strength in 4 
tumor-bearing mice. Control and Tumor-bearing mice were administered vehicle or 5 
minocycline (Mino) in the drinking water starting one day after tumor cell injection. A) Control 6 
and Tumor mice were exposed to the forced swim test at 2 weeks and total time immobile was 7 
determined. B) Grip strength was assessed and normalized to body mass at the 3 week endpoint. 8 
C) Tumor mass, D) muscle mass, and E) plasma IL-6 levels were determined at 3 weeks. Means 9 
with * are different from control mice (p<0.05), means with ‡ are different from Tumor-Vehicle 10 
mice (p<0.05) (n=8-12). 11 
 12 
Figure 5. Minocycline attenuated neuroinflammation in tumor-bearing mice. Control and 13 
Tumor-bearing mice were administered vehicle or minocycline (Mino) in the drinking water. A-14 
D) IL-1β and IL-6 mRNA expression was determined in the HPC and CX at 3 weeks. Data are 15 
expressed as mean ± SEM. Means with * are different from control mice (p<0.05), means with + 16 
tend to be different from control mice (p=0.07) (n=8-12). 17 
18 
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 1 
 2 
Table 1: Soleus in vitro contractile properties. 3 
Parameters Control Tumor 
Week 1 
Tumor 
Week 2 
Tumor 
Week 3 
Twitch     
Time to peak (ms) 52 ± 4 90 ± 7* 81 ± 5* 79 ± 1* 
Time to relax 50% (ms) 82 ± 10 259 ± 41* 206 ± 28* 167 ± 33* 
Absolute force (mN) 52 ± 3 51 ± 3 46 ± 3 45 ± 4 
Specific force (kN/m2) 86 ± 5 95 ± 4 95 ± 6 94 ± 7 
Tetanus     
Time to relax 50% (ms) 151 ± 5 178 ± 11 161 ± 8 198 ± 20 
Absolute force (mN) 206 ± 14 180 ± 6 158 ± 11* 153 ± 9* 
Specific force (kN/m2) 339 ± 20 336 ± 13 324 ± 22 316 ± 19 
Fatigue (2 min /initial 
force) 
0.53 ± 0.03 0.42 ± 0.03 0.47 ± 0.02 0.50 ± 0.06 
Number of mice 6 6 6 6 
 4 
Mice were inoculated s.c. with PBS (Control) or PBS with C26 adenocarcinoma cells (Tumor). 5 
Control and tumor mice were sacrificed at 1, 2 or 3 weeks after tumor cell inoculation and 6 
contractile properties of soleus skeletal muscle were determined in vitro (n=6). Values are mean 7 
± sem. Means with * are different from control mice (p<0.05). 8 
9 
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 1 
 2 
Table 2: EDL in vitro contractile properties. 3 
Parameters Control Tumor 
Week 1  
Tumor 
Week 2 
Tumor 
Week 3 
Twitch     
Time to peak (ms) 26 ± 1 21 ± 1* 21 ± 1* 29 ± 2 
Time to relax 50% (ms) 41 ± 4 31 ± 2 23 ± 1* 45 ± 5 
Absolute force (mN) 124 ± 5 93 ± 3* 98 ± 7* 91 ± 11* 
Specific force (kN/m2) 139 ± 5 125 ± 6 129 ± 8 137 ± 13 
Tetanus     
Time to relax 50% (ms) 58 ± 3 55 ± 2 52 ± 1 64 ± 4 
Absolute force (mN) 326 ± 14 251 ± 9* 288 ± 21 249 ± 29* 
Specific force (kN/m2) 366 ± 17 336 ± 16 380 ± 23 373 ± 36 
Fatigue (2 min/initial force) 0.09 ± 0.02 0.09 ± 0.01 0.08 ± 0.01 0.10 ± 0.01 
Number of mice 6 6 6 6 
 4 
Mice were inoculated s.c. with PBS (Control) or PBS with C26 adenocarcinoma cells (Tumor). 5 
Control and tumor mice were sacrificed at 1, 2 or 3 weeks after tumor cell inoculation and 6 
contractile properties of Extensor digitorum longus (EDL) skeletal muscle were determined in 7 
vitro (n=6). Values are mean ± sem. Means with * are different from control mice (p<0.05).  8 
 9 
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Table 3: Tibialis in situ contractile properties. 3 
Parameters Control Tumor 
Twitch    
Time to peak (ms) 30 ± 2 27 ± 1 
Time to relax 50% (ms) 30 ± 3 27 ± 2 
Time to relax 90% (ms) 66 ± 7 57 ± 4 
Absolute force (mN) 417 ± 15 353 ± 16* 
Specific force (kN/m2) 120 ± 4 141 ± 4 
Tetanus   
Time to relax 50% (ms) 56 ± 4 50 ± 4 
Time to relax 90% (ms) 96 ± 9 88 ± 8 
Absolute force (mN) 1127 ± 65 859 ± 48* 
Specific force (kN/m2) 323 ± 17 329 ± 18 
Fatigue (2 min force/initial force) 0.22 ± 0.04 0.29 ± 0.08 
Number of mice 6 6 
 4 
Mice were inoculated s.c. with PBS (Control) or PBS with C26 adenocarcinoma cells (Tumor). 5 
In situ contraction analyses of the tibialis were determined 3 weeks after tumor cell inoculation 6 
(n=6). Values are mean ± sem. Means with * are different from control mice (p<0.05). 7 
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